Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third Rock goes bi-coastal, pumping $41M into SF blood diseases start-up

This article was originally published in Scrip

Executive Summary

The latest start-up backed by Third Rock Ventures, Global Blood Therapeutics, has come out of stealth mode after two years. With a Series A funding of $40.7 million, Third Rock, a prolific early-stage investor in East Coast startups, is now funding its first "de novo" startup on the West Coast. Global Blood Therapeutics, based in San Francisco, aims to find oral small molecule drugs to treat severe, genetic blood diseases. With a new West Coast office, the venture firm now hopes to operate with an expanded, bi-coastal model.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts